Thanks to pharma's R&D cost-cutting efforts, the CRO industry will expand at nearly a 10% clip through 2019, a new report says, citing trends that many industry-watchers will find familiar.
Swedish contractor Recipharm inked a deal with Israeli biotech RedHill Biopharma to produce the company's leading drug candidate for clinical trials and an expected commercial launch.
A few months ago, the European Medicines Agency followed through on a threatened continental marketing halt affecting about 700 drugs in Indian CRO GVK Biosciences' generic lineup due to allegations of manipulated trial results. Now, Germany's regulators have suspended another 54 drugs tested by GVK in accordance with the EMA's recommendations.
Accutest Research Laboratories moved to expand in Latin America, announcing on Monday that it is establishing offices and operations in Brazil.
Market-access contractor DKSH has signed a deal with Actelion Pharmaceuticals to help the company bolster its position in Asia.
Concept Life Sciences, a CRO pieced together through a string of acquisitions, has inked a deal to acquire a toxicology-focused contractor, looking to expand its palate of drug development services.
Germany's Evotec grew its revenue 37% in the first half of 2015, as its CRO-like business brought in cash to support the company's in-house R&D.
Chinese CRO WuXi Pharma posted more soaring revenue in the second quarter, but some costly investments and currency issues drove down the company's profits as it prepares to go private.
The deep-pocketed outfits that helped take INC Research public last year are angling to cash in on the CRO's resulting success on the market, flipping shares in a secondary offering.
U.S. CRO Accelovance is blueprinting a new site in Wales, planning to add 70 positions as it builds out its European ranks.
Chinese CRO WuXi PharmaTech, alongside partner TruTag Technologies, is developing tiny, edible bar codes designed to prevent drug counterfeiting, and the technology cleared its first hurdle.
An Indian CRO that counts Johnson & Johnson, Novartis and Sanofi among its clients is under fire from the FDA for repeated quality control issues, the latest ding to the country's reputation as a go-to destination for outsourced drug development.
Two mid-size CROs are slated to merge and contend with the industry's titans, as Chiltern is buying Theorem Clinical Research in a move to strengthen its global presence.
Contract drugmaker Patheon inked a deal to manufacture Flexion Therapeutics' top prospect as it moves through clinical development.
Two years after Quintiles' trend-setting IPO, the CRO's private equity owners are still profiting from the company's continued growth, pocketing $545 million in a secondary offering.
Irish CRO Icon has signed on to be the exclusive service provider for a new U.K. biotech startup, planning to help the nascent company advance a trio of Novartis-developed drugs.
AMRI, rebuilding its business after a string of slow quarters, posted a profit for the first time in 12 months as it looks to hit its stride as a growing contract drug developer.
Parexel International, slashing jobs after a rough run, posted some modest revenue gains in its fiscal fourth quarter, and now the CRO is looking to build some momentum with a jump in new business.
CRO INC Research posted another quarter of double-digit revenue growth, lifting its 2015 guidance for the second time to account for a jump in new business.
Contract drugmaker Patheon is getting out of agrochemicals and selling off a manufacturing plant, narrowing its focus on pharmaceutical development as it plots an IPO.